Quadramet is indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radonuclide bone scan More
62% to 72% of patients experienced relief1
Moderate, predictable, and transient myelosuppression2
16-week duration of relief with a single 1.0 mCi/kg injection1
Acts systemically to target multiple lesion sites3
REFERENCES:
Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940-945.